Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis

Iskandar, Agustin; Arthamin, Maimun Z; Indriana, Kristin; Anshory, Muhammad; Hur, Mina; Somma, Salvatore Di

doi:10.1080/14767058.2018.1475643

Cited by 23 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No better than PCT regardless of the presence or not of AKI [17] Neonates with SIRS and positive blood cultures Neonates with SIRS with negative blood cultures Better than PCT [81] Better performance when combined with PCT and/or CRP…”

Section: Patients With Proven Viral Lower Respiratory Infectionmentioning

confidence: 99%

Biomarkers of sepsis: time for a reappraisal

et al. 2020

View full text Add to dashboard Cite

Introduction: Sepsis biomarkers can have important diagnostic, therapeutic, and prognostic functions. In a previous review, we identified 3370 references reporting on 178 different biomarkers related to sepsis. In the present review, we evaluate the progress in the research of sepsis biomarkers.Methods: Using the same methodology as in our previous review, we searched the PubMed database from 2009 until September 2019 using the terms "Biomarker" AND "Sepsis." There were no restrictions by age or language, and all studies, clinical and experimental, were included.Results: We retrieved a total of 5367 new references since our previous review. We identified 258 biomarkers, 80 of which were new compared to our previous list. The majority of biomarkers have been evaluated in fewer than 5 studies, with 81 (31%) being assessed in just a single study. Apart from studies of C-reactive protein (CRP) or procalcitonin (PCT), only 26 biomarkers have been assessed in clinical studies with more than 300 participants. Forty biomarkers have been compared to PCT and/or CRP for their diagnostic value; 9 were shown to have a better diagnostic value for sepsis than either or both of these biomarkers. Forty-four biomarkers have been evaluated for a role in answering a specific clinical question rather than for their general diagnostic or prognostic properties in sepsis. Conclusions:The number of biomarkers being identified is still increasing although at a slower rate than in the past. Most of the biomarkers have not been well-studied; in particular, the clinical role of these biomarkers needs to be better evaluated.

show abstract

Section: Patients With Proven Viral Lower Respiratory Infectionmentioning

confidence: 99%

Biomarkers of sepsis: time for a reappraisal

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It should again be recognised that the patient cohorts in these studies were fairly small (fewer than 50 in most) which must be considered as a limiting factor. A similarly sized study reported a lower AUC of 0.758 for presepsin, while also reporting an AUC of 0.599 for PCT [55]. The value for PCT was also lower than has generally been reported in other studies considered previously.…”

Section: Neonatesmentioning

confidence: 48%

“…In the neonatal group, they suggested that PCT has moderate diagnostic accuracy, but further studies are required. A more recent study that investigated the use of presepin and PCT for the diagnosis of early neonatal sepsis also suggested that PCT performed relatively poorly, calculating the area under the curve (AUC) for PCT as 0.599 [55]. This study did have some limitations in that the study group was fairly small (51 neonates) and there was no defined control group.…”

Section: Neonatesmentioning

confidence: 96%

Biomarkers for Point-of-Care Diagnosis of Sepsis

2020

View full text Add to dashboard Cite

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In 2017, almost 50 million cases of sepsis were recorded worldwide and 11 million sepsis-related deaths were reported. Therefore, sepsis is the focus of intense research to better understand the complexities of sepsis response, particularly the twin underlying concepts of an initial hyper-immune response and a counter-immunological state of immunosuppression triggered by an invading pathogen. Diagnosis of sepsis remains a significant challenge. Prompt diagnosis is essential so that treatment can be instigated as early as possible to ensure the best outcome, as delay in treatment is associated with higher mortality. In order to address this diagnostic problem, use of a panel of biomarkers has been proposed as, due to the complexity of the sepsis response, no single marker is sufficient. This review provides background on the current understanding of sepsis in terms of its epidemiology, the evolution of the definition of sepsis, pathobiology and diagnosis and management. Candidate biomarkers of interest and how current and developing point-of-care testing approaches could be used to measure such biomarkers is discussed.

show abstract

“…In the last few years, PCT has been investigated as a promising early biomarker in the diagnosis of neonatal infections and different results have been published [17], [27] . In these studies, PCT values ranged from 0.5 to 25 ng/mL [23] , the reported PCT sensitivity for the diagnosis of early onset sepsis was found to be 30-100% while the specificity was 51-100% [17] .…”

Section: Resultsmentioning

confidence: 99%

Whether Cord Blood or Venous Blood Procalcitonin Level for Better Prediction of Maternofetal Infections in Algerian Newborns?

Adouani

Djabi

Hang

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

This prospective study aims to measure and compare the level of umbilical cord blood and venous blood procalcitonin (PCT) for a better and more rapid prediction of maternofetal infections in Algerian newborns. The study was conducted at the hospital of child and mother of Setif in Algeria from 2016 to 2018. 164 Algerian term suspected newborns born alive to mothers with Maternofetal infection (MFI) risk factors were included. 69 non-infectious newborns born alive to mothers without MFI risk factors served as the control group. The venous blood and cord blood in each group were collected. PCT levels were determined and compared to CRP levels. Receiver operating curves (ROC) were generated to detect the best cut-off values for sensitivity and specificity. Levels of both cord blood and venous blood procalcitonin were significantly higher in the suspected group than those in the control group (P<0.05). According to the ROC curve, at the cut-off value of cord blood PCT of 0.595 ng/mL, the sensitivity and specificity were 92.3 %, 91.8 % respectively. At the cut-off value of venous blood PCT of 1.12 ng/mL, the sensitivity and specificity were 100%, 80.5% respectively. The diagnostic value of cord blood PCT for maternofetal infections is higher than venous blood PCT. Keywords: Algerian term newborns, Cord blood, Procalcitonin, Maternofetal infections.

show abstract

Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis

Abstract: In early diagnosis of neonatal sepsis, compared with procalcitonin, presepsin seems to provide better early diagnostic value with consequent possible faster therapeutical decision making and possible positive impact on outcome of neonates.

Cited by 23 publications

References 21 publications

Biomarkers of sepsis: time for a reappraisal

Biomarkers of sepsis: time for a reappraisal

Biomarkers for Point-of-Care Diagnosis of Sepsis

Whether Cord Blood or Venous Blood Procalcitonin Level for Better Prediction of Maternofetal Infections in Algerian Newborns?

Contact Info

Product

Resources

About